A naukri.com initiative
Bioengineer
6d
181
Image Credit: Bioengineer
Immune Checkpoint Inhibitors Boost Efficacy of Standard Chemotherapy in Stage 3 Colon Cancer, Study Shows
- Research presented at the 2025 ASCO Meeting reveals that combining immune checkpoint inhibitor atezolizumab with standard chemotherapy improves disease-free survival in stage 3 colon cancer patients with deficient mismatch repair.
- The ATOMIC trial, involving 712 patients with microsatellite instability-high tumors, evaluated atezolizumab with FOLFOX chemotherapy to reduce cancer recurrence rates post-surgery.
- Traditionally, FOLFOX chemotherapy has been the post-surgical standard treatment, but recurrence rates in dMMR tumors pose challenges.
- The study's primary endpoint was disease-free survival, with patients undergoing combination therapy showing a significant increase in three-year DFS rates compared to chemotherapy alone.
- dMMR tumors, with high mutational burden, increase neoantigen presentation, enhancing tumor immunogenicity and the efficacy of immunotherapy.
- The ATOMIC trial's international collaboration model, led by NCI and involving Genentech and the German AIO group, highlights the importance of multi-institutional partnerships in cancer research.
- The findings could revolutionize post-operative colon cancer treatment, with the combination therapy demonstrating manageable side effects and potentially becoming a new standard of care.
- Dr. Jeffrey Meyerhardt emphasizes the transformative impact of the study, pointing to the convergence of precision medicine and immuno-oncology in advancing cancer therapeutics.
- The success of the trial lays the groundwork for further exploration of adjuvant immunotherapy in different tumor profiles and stages, signaling a shift towards precision oncology and personalized cancer care.
- Overall, the ATOMIC study showcases the potential of combining atezolizumab with chemotherapy to enhance treatment efficacy in a specific subset of colon cancer patients, marking a significant advancement in cancer care.
Read Full Article
10 Likes
For uninterrupted reading, download the app